CAMP4 Therapeutics Corporation (CAMP) Price & Analysis

Compare

108 Followers

CAMP Stock Chart & Stats

$4.10

-$0.13(-2.84%)

At close: Jan 08 4:00 PM EST

$4.10

-$0.13(-2.84%)

Day’s Range― - ―

52-Week Range$1.31 - $10.80

Previous Close$4.45

Volume38.22K

Average Volume (3M)1.59M

Market Cap

$76.01M

Enterprise Value-$2.60M

Total Cash (Recent Filing)$39.05M

Total Debt (Recent Filing)$7.22M

Price to Earnings (P/E)―

Beta1.86

Next Earnings

Nov 20, 2025

EPS Estimate

-0.47

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.62

Shares Outstanding20,161,074

10 Day Avg. Volume141,089

30 Day Avg. Volume1,592,597

Financial Highlights & Ratios

PEG Ratio-0.35

Price to Book (P/B)1.61

Price to Sales (P/S)156.16

P/FCF Ratio-2.21

Enterprise Value/Market Cap-0.03

Enterprise Value/Revenue-0.68

Enterprise Value/Gross Profit-0.68

Enterprise Value/Ebitda0.05

Forecast

1Y Price Target

$8.50

Price Target Upside107.32% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial PerformanceThe company has raised $50M in a private placement, providing a financial runway into 2027 and demonstrating investor confidence.

Strategic PartnershipsThe involvement of the Syngap Research Fund, known for its activity in the SYNGAP1 patient community, is expected to aid significantly in patient identification and enrollment.

Technological AdvancementCAMP4's proprietary RNA-based technology platform shows strong potential to target a wide spectrum of haploinsufficient diseases.

Bears Say

Investment StrategyCAMP will not make any additional investment in the CMP-CPS-01 program and will explore partnership opportunities instead.

Program ChallengesThe variability in ureagenesis data for CMP-001 is viewed as somewhat disappointing given the lack of clinical validation that targeting RegRNA can impart pharmacodynamic changes.

Program DevelopmentThe lead program, CMP-SYNGAP-01 for SYNGAP-related disorders, is in a very early stage with a long time horizon to patient level value creation.

CAMP4 Therapeutics Corporation News

Strategic Focus and Financial Strength Drive Buy Rating for CAMP4 Therapeutics

Analyst Yun Zhong of Wedbush reiterated a Buy rating on CAMP4 Therapeutics Corporation, retaining the price target of...

8d ago

CAMP

Camp4 Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Camp4 Therapeutics (CAMP) with an Overweight rating and $7 price target Camp4 is...

1M ago

CAMP

Camp4 Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Camp4 Therapeutics (CAMP) with an Overweight rating and $7 price target Published first...

1M ago

CAMP

CAMP4 Initiates GLP Toxicology Studies for CMP-SYNGAP-01

CAMP4 Therapeutics Corporation ( ($CAMP) ) has provided an update. On October 1, 2025, CAMP4 Therapeutics announced the...

2M ago

CAMP

Camp4 Therapeutics initiates GLP toxicology studies for CMP-SYNGAP-01

CAMP4 Therapeutic announced the initiation of toxicology studies conducted under Good Laboratory Practice standards for its lead product...

2M ago

CAMP

Promising Prospects for CAMP4 Therapeutics: Buy Rating Affirmed Amid Advancements in CMP-SYNGAP-01 Program and Strong Investor Confidence

Wedbush analyst Yun Zhong has reiterated their bullish stance on CAMP stock, giving a Buy rating on September...

2M ago

CAMP

Apple initiated, Hershey upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

HPE

Camp4 Therapeutics downgraded to Neutral from Overweight at JPMorgan

JPMorgan analyst Anupam Rama downgraded Camp4 Therapeutics (CAMP) to Neutral from Overweight without a price target The company’s...

2M ago

CAMP

Camp4 Therapeutics price target lowered to $12 from $18 at Piper Sandler

Piper Sandler analyst Edward Tenthoff lowered the firm’s price target on Camp4 Therapeutics (CAMP) to $12 from $18...

2M ago

CAMP

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

2M ago

CAMP

CAMP4 Therapeutics Secures $100M in Private Placement

An update from CAMP4 Therapeutics Corporation ( ($CAMP) ) is now available. On September 9, 2025, CAMP4 Therapeutics...

2M ago

CAMP

Camp4 Therapeutics announces oversubscribed private placement up to $100M

CAMP4 Therapeutics (CAMP) entered into definitive securities purchase agreements with certain institutional and accredited investors for up to...

2M ago

CAMP

Camp4 Therapeutics appoints Doug Williams as board chair, Dan Tardiff as CSO

Concurrently with the financing, James Boylan, Ravi Thadhani, M.D., and Paula Ragan, Ph.D., have resigned from the Board...

2M ago

CAMP

CAMP4 Therapeutics Reports Q2 2025 Progress and Outlook

CAMP4 Therapeutics Corporation ( ($CAMP) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

CAMP

CAMP FAQ

What was CAMP4 Therapeutics Corporation’s price range in the past 12 months?

CAMP4 Therapeutics Corporation lowest stock price was $1.30 and its highest was $10.80 in the past 12 months.

What is CAMP4 Therapeutics Corporation’s market cap?

CAMP4 Therapeutics Corporation’s market cap is $76.01M.

When is CAMP4 Therapeutics Corporation’s upcoming earnings report date?

CAMP4 Therapeutics Corporation’s upcoming earnings report date is Nov 20, 2025 which is in 4 days.

How were CAMP4 Therapeutics Corporation’s earnings last quarter?

CAMP4 Therapeutics Corporation released its earnings results on Aug 14, 2025. The company reported -$0.62 earnings per share for the quarter, beating the consensus estimate of -$0.673 by $0.053.

Is CAMP4 Therapeutics Corporation overvalued?

According to Wall Street analysts CAMP4 Therapeutics Corporation’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does CAMP4 Therapeutics Corporation pay dividends?

CAMP4 Therapeutics Corporation does not currently pay dividends.

What is CAMP4 Therapeutics Corporation’s EPS estimate?

CAMP4 Therapeutics Corporation’s EPS estimate is -0.47.

How many shares outstanding does CAMP4 Therapeutics Corporation have?

CAMP4 Therapeutics Corporation has 20,161,074 shares outstanding.

What happened to CAMP4 Therapeutics Corporation’s price movement after its last earnings report?

CAMP4 Therapeutics Corporation reported an EPS of -$0.62 in its last earnings report, beating expectations of -$0.673. Following the earnings report the stock price went up 7.742%.

Which hedge fund is a major shareholder of CAMP4 Therapeutics Corporation?

Currently, no hedge funds are holding shares in CAMP

CAMP4 Therapeutics Corporation Stock Smart Score

Neutral

Company Description

CAMP4 Therapeutics Corporation

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

CAMP4 Therapeutics Corporation (CAMP) Earnings & Revenues

Historic Earnings Reports

CAMP Stock 12 Month Forecast

Average Price Target

$8.50

▲(107.32% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Jan<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.16,4.763076923076923,5.366153846153846,5.969230769230769,6.572307692307692,7.1753846153846155,7.7784615384615385,8.381538461538462,8.984615384615385,9.587692307692308,10.19076923076923,10.793846153846154,11.396923076923077,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.16,4.493846153846154,4.827692307692308,5.161538461538462,5.495384615384616,5.82923076923077,6.163076923076924,6.496923076923077,6.830769230769231,7.164615384615384,7.498461538461539,7.832307692307692,8.166153846153847,{"y":8.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.16,4.378461538461538,4.596923076923077,4.815384615384615,5.033846153846154,5.252307692307692,5.470769230769231,5.689230769230769,5.907692307692308,6.126153846153846,6.344615384615384,6.563076923076923,6.781538461538462,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.75,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.75,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.75,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.05,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.05,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.07,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.22,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.91,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.88,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.65,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >